New Cholesterol Pill Cuts LDL by 60%, Reduces Heart Risks
A new oral cholesterol medication from Merck has demonstrated a remarkable 60% reduction in LDL (bad) cholesterol levels in adults with a genetic form of high cholesterol. Published in JAMA, the research also showed the pill, enlicitide, reduced heart attack and stroke rates by 20% in high-risk patients within just one year.
Key Takeaways
- Lowers LDL cholesterol by approximately 60% in genetic high cholesterol patients.
- Reduces heart attack and stroke risk by 20% within one year.
- Targets patients with HeFH, a condition affecting 1 in 250 people.
- Works by blocking the PCSK9 liver protein.
- Merck plans to seek FDA approval early next year.
Who Can Benefit From This New Treatment?
The pill is designed for patients with Heterozygous Familial Hypercholesterolemia (HeFH), an inherited condition affecting roughly 1 in 250 people. HeFH impairs the body’s ability to remove LDL cholesterol, significantly raising the risk of early-onset atherosclerotic cardiovascular disease (ASCVD)—a dangerous buildup of fatty deposits in the arteries.
How the New Cholesterol Pill Works
Enlicitide works by blocking a specific liver protein called PCSK9, which normally prevents the body from eliminating cholesterol. By inhibiting PCSK9, the pill helps the body clear LDL cholesterol from the bloodstream more effectively. This mechanism delivered not only dramatic cholesterol reduction but also a direct, rapid benefit to heart health.
“Enlicitide was designed to deliver PCSK9 antibody-like efficacy and specificity in an easy-to-use pill,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “Enlicitide, if approved, adds to physicians’ armamentarium to lower LDL-C.”
Clinical Trial Results
The 52-week global trial involved over 300 adults with HeFH from 17 countries, all of whom were already on statins or other cholesterol therapies. Participants were randomly assigned to receive either a daily 20 mg Enlicitide pill or a placebo.
- At 24 weeks: The Enlicitide group saw LDL cholesterol levels drop by 58.2%, while the placebo group saw no change.
- At 52 weeks: The Enlicitide group maintained a 55.3% reduction, whereas the placebo group’s cholesterol levels increased by 8.7%.
Why Lowering LDL Cholesterol is Critical
Decades of research, including from Harvard Health, confirm that reducing LDL cholesterol lowers the risk of cardiovascular death, heart attacks, strokes, and the need for bypass surgeries. This is true for patients with existing coronary artery disease and for those at high risk without it.
This new therapy is aimed at patients who cannot reach their cholesterol targets with existing medications. Merck plans to apply for FDA approval early next year.
